Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Pursuit of tumor-infiltrating lymphocyte immunotherapy speeds up
Mounting evidence of efficacy in metastatic breast cancer and other epithelial tumors is driving clinical and commercial investment in tumor-infiltrating lymphocytes.
At the beginning of July, Iovance Biotherapeutics announced that the US Food and Drug Administration may consider its ongoing phase 2 study of tumor-infiltrating lymphocyte (TIL) therapy LN-145 sufficient to support registration as a treatment for advanced cervical cancer. This therapy—which involves extracting T cells from a patient’s tumor, expanding them ex vivo and reinjecting them—is one of several TIL treatments showing encouraging results in the clinic. Other groups are also joining the fray, pursuing TILs for various solid cancers (Table 1).
